Nkarta, Inc.
Nkarta Therapeutics, Inc. (Nasdaq: NKTX) is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer cell therapies. The company's website is www.nkartatx.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Nkarta, Inc. does
In the company’s own words
Nkarta Therapeutics, Inc. (Nasdaq: NKTX) is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer cell therapies. The company's website is www.nkartatx.com.
Nkarta's core business focuses on developing chimeric antigen receptor natural killer cell therapies designed to treat autoimmune diseases and other conditions. The company's lead pipeline program is NKX019, a CAR NK product candidate targeting the CD19 antigen for treating patients with autoimmune diseases including lupus nephritis, primary membranous nephropathy, systemic sclerosis, idiopathic inflammatory myopathy, and antineutrophil cytoplasmic antibody-associated vasculitis. NKX019 is currently being studied in multiple Phase 1 clinical trials, including the Ntrust-1 trial for lupus nephritis and primary membranous nephropathy, the Ntrust-2 trial for additional autoimmune indications, and investigator-sponsored trials at Columbia University and University of California institutions.
The company's proprietary CAR NK platform is built on five core technologies: NK cell expansion using engineered stimulatory cells, persistence enhancement through membrane-bound interleukin-15 engineering, optimized targeting and signaling through CAR design, genome editing capabilities using CRISPR-Cas9 technology, and cryopreservation techniques enabling off-the-shelf administration. This modular platform approach allows Nkarta to generate engineered NK cells from healthy donor sources, providing abundant supply and consistent manufacturing compared to autologous cell therapies.
Nkarta operates two good manufacturing practice facilities in South San Francisco, California. The company's first facility, a 2,700-square-foot clinical cGMP site, currently produces clinical supply. The second facility includes a 12,500-square-foot cGMP manufacturing area alongside research and development and corporate headquarters space. The company manufactures certain materials and components through third-party contract manufacturers while maintaining internal control over critical manufacturing steps.
The company has not generated revenue from product sales and remains in the clinical development stage. Nkarta's strategy emphasizes developing innovative, broadly accessible cell therapies for autoimmune diseases while advancing its manufacturing capabilities to enable scalable, cost-effective production for both clinical trials and potential commercial supply.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1787400
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Nkarta, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Nkarta, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Nkarta, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Nkarta, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Nkarta, Inc.'s last four quarterly filings that the numbers alone won't show?”